Videos

Expert perspectives on the ALPINE trial of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Andrew Lipsky, MD, considers the role of BTK inhibitors as second-line therapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Joseph M. Scandura, MD, PhD, discusses research regarding pelabresib for patients with myeloproliferative neoplasms.

Michael Wang, MD, discusses the background of the phase 3 BRUIN MCL-321 trial and how positive results may shape the future of the mantle cell lymphoma space.

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.

A review of recently updated data from KEYNOTE-671, focused on perioperative use of pembrolizumab in early-stage non–small cell lung cancer.

Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.

Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).

Jeffrey Dome, MD, PhD, discusses how the use of atezolizumab has impacted the treatment of pediatric patients with alveolar soft part sarcoma.

A discussion on the toxicities associated with mTOR inhibitors and which patients with PEComa would be considered good candidates.

Dr Andrew Wagner shares data from the AMPECT trial investigating the potential role of mTOR inhibitors in PEComa.

Jonathan C. Trent, MD, PhD, discusses the molecular analyses of the INTRIGUE study, which was supported by Caris Life Science’s Precision Oncology Alliance, investigating patients with GIST that were presented at ASCO 2023.

Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.

Following their interview with Stephanie Graff, MD, FACP, the Oncology Brothers share key takeaways from the NATALEE, SONIA, and X-7/7 trials and consider how they will impact the management of breast cancer.

The Oncology Brothers, joined by Stephanie Graff, MD, FACP, share their thoughts on data from the X-7/7 trial of fixed-dose capecitabine in patients with metastatic breast cancer.

Shared insight from the Oncology Brothers and Stephanie Graff, MD, FACP, on the role of CDK4/6 inhibition in combination with aromatase inhibitor therapy following data from the SONIA trial in HR+ metastatic breast cancer.

Expert oncologist Stephanie Graff, MD, FACP, joins the Oncology Brothers to review data from the NATALEE trial and consider the role of adjuvant ribociclib in patients with HR+ breast cancer.

Nicholas J. Roberts, discusses real-world research around the adoption of germline testing for breast cancer, and the testing gap in certain racial groups.

Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.

Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.

David S. Hong, MD, discusses which disease subgroups may benefit from treatment with larotrectinib.

Cyrus M. Khan, discusses the current use of PI3K inhibitors to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and how recent ODAC decisions impacted their use.

Craig Horbinski, MD, PhD, discusses the classification of gliomas based on histology and molecular features.

Dennis J. Slamon, MD, discusses the rationale of the phase 3 NATALEE trial and ribociclib for the treatment of patients with HR+/HER2- early breast cancer.

Rohan Garje, MD, discusses the goals of his research in assessing the outcomes of sarcomatoid vs classic urothelial carcinoma of bladder.

Ashwin Kishtagari, MD, discusses the PERSIST-2 trial of pacritinib for patients with primary myelofibrosis and low platelet counts.

Dr Amy Dezern discusses the criteria for subtype classification and risk stratification in patients with MDS.

Amy Dezern, MD, MHS, shares the case of a 70-year-old man with MDS stratified as low-risk using the Revised International Prognostic Scoring System.

Lisa B. Ercolano, MD, discusses the treatment of sarcomas in an era of molecular medicine.

Dr Elizabeth Davis presents the case of a young woman with a TSC2-mutated uterine PEComa.